AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$GKOS

Navratil Tomas sold $243K of GKOS

Navratil Tomas (CHIEF DEVELOPMENT OFFICER) sold 1,457 shares of GLAUKOS Corp (GKOS) at an average of $166.92 ($163.20–$172.00, $0.24M total) across 7 trades on 2026-09-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Navratil Tomas
Published Sep 18, 2026, 9:32 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 18, 2026, 9:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$GKOS
Neutral
high confidence
Mentioned
$GKOS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GKOSNeutralLow
01

Why it matters

The disclosed sale is routine and modest; investors should monitor for any subsequent insider activity.

02

Market read

Minor insider sell; low trading relevance.

03

What to watch

Potential tax or liquidity reasons for the sale; not necessarily a confidence issue.

Relevance 3/10Novelty 3/10Timing: post‑market 2026‑09‑16

Background

Form 4 filings disclose insider transactions; a 10b5‑1 plan indicates pre‑arranged trades.

Company-level read

Ticker impact

$GKOSNeutralHigh confidence
Context

Chief Development Officer Navratil Tomas sold 1,457 shares for $243K via a 10b5‑1 plan, reducing his stake to 72,433 shares.

Expected impact

No significant impact expected.

Evidence & confidence

The sale size is small relative to market cap and follows a pre‑arranged plan, indicating routine portfolio rebalancing rather than loss of confidence.

Market effects

Sector

None; the transaction is company‑specific.

Regional

None; limited to GKOS shareholders.

Global

None

Counterpoint

What could challenge this read

If the insider is offloading shares, it could signal upcoming negative news.

Key entities

  • person
    Navratil Tomas

    Chief Development Officer of GLAUKOS Corp.

  • company
    GLAUKOS Corp

    Ticker GKOS, a US‑listed biotech.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

GKOS insider trading history →

Related articles

$MGRCMed

McGrath RentCorp Soars 9% as It Prepares to Join the S&P SmallCap 600

McGrath RentCorp (MGRC) shares rose 9% on Monday after being added to the S&P SmallCap 600 index. The company cut its revenue outlook last week and is increasing capital expenditure. S&P SmallCap 600 index funds must buy MGRC shares by November 4. Glaukos (GKOS) and Loar Holdings (LOAR) are also being added to the S&P MidCap 400 and S&P SmallCap 600, respectively.

finance.yahoo.com
$GKOSHighAI 9/10

Glaukos (GKOS) Stock Soars After Blowout Q3 Earnings Beat

Glaukos (GKOS) stock surged 33.65% after Q3 earnings beat expectations, reporting EPS of $0.47 vs. -$0.09 and revenue of $211M vs. $168.1M. The company raised FY26 and FY27 revenue guidance, citing strong performance of iDose TR and Epioxa. Analysts upgraded price targets, with BTIG at $205 and Mizuho at $190.

timothysykes.com
$GKOSHighAI 8/10

Glaukos (GKOS) Stock Surges After Massive Earnings Beat

Glaukos (GKOS) stock surged 32.57% on October 29, 2026, after reporting Q3 revenue of $211M (vs. $168M expected) and adjusted EPS of $0.47 (vs. projected loss). The company raised its 2026 revenue guidance to $775M–$785M and 2027 to $1.0B. Positive clinical data for iDose TR and Epioxa, along with a retinal deal, supported the rally. GKOS closed at $240.52, up from $181.43 the prior day. Analysts raised price targets, with BTIG at $205 and Mizuho at $190.

stockstotrade.com
$GKOSHighAI 9/10

Glaukos (GKOS) Stock Surges After Earnings Beat And Bullish Guidance

Glaukos (GKOS) stock surged 32.65% after reporting Q3 earnings that beat expectations, with adjusted EPS of $0.47 vs. an expected loss. Revenue was $211M, exceeding the $168M consensus. The company raised its 2026 revenue guidance to $775M–$785M and set a 2027 target of $1.0B. Analysts maintained buy ratings with adjusted price targets.

timothysykes.com
$GKOSMedAI 8/10

Piper Sandler raises Glaukos stock price target on Epioxa strength

Piper Sandler raised its price target on Glaukos (GKOS) to $240 from $195, citing strong Q3 results. Revenue was $211.0M, up 58% YoY, beating estimates. The company also raised its fiscal 2026 revenue guidance to $775M-$785M. GKOS stock has surged 135% over the past year, trading near its 52-week high at $229.12. Other analysts also raised price targets, citing strong performance and pipeline progress.

investing.com